Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Key Stats

• Today's Range: $15.65 to $16.52
• 50-Day Range: $14.71 to $18.88
• 52-Week Range: $9.57 to $29.86
• Volume: 2.45 million shs
• Average Volume: 1.97 million shs
• Market Capitalization: $2.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.71
• Consensus Rating: Moderate Buy

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

Arrowhead Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 212th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arrowhead Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arrowhead Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Arrowhead Pharmaceuticals has a PEG Ratio of 18.72. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Arrowhead Pharmaceuticals has a P/B Ratio of 10.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.55% of the float of Arrowhead Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arrowhead Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.55

Percentage of Shares Shorted

9.55% of the float of Arrowhead Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.82

News Sentiment

Arrowhead Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Arrowhead Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

16 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

3 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.

Percentage Held by Institutions

62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARWR Stock Analysis - Frequently Asked Questions

How have ARWR shares performed this year?

Arrowhead Pharmaceuticals' stock was trading at $18.80 at the beginning of 2025. Since then, ARWR shares have decreased by 13.5% and is now trading at $16.26.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Monday, May, 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The biotechnology company earned $542.71 million during the quarter, compared to analyst estimates of $116.27 million.
Read the conference call transcript.

Who are Arrowhead Pharmaceuticals' major shareholders?

Top institutional investors of Arrowhead Pharmaceuticals include Aberdeen Group plc (0.70%), Wealth Effects LLC (0.12%), Platinum Investment Management Ltd. (0.08%) and Pinion Investment Advisors LLC (0.05%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener.
View institutional ownership trends.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/24/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARWR
• CIK: 879407
• Web: www.arrowheadpharma.com
• Phone: (626) 304-3400
• Fax: 626-304-3401
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Arrowhead Pharmaceuticals: $43.71
• High Price Target: $80.00
• Low Price Target: $17.00
• Potential Upside/Downside: +170.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 17.59
• Net Income: -$599.49 million
• Net Margins: N/A
• Pretax Margin: -27.93%
• Return on Equity: -45.33%
• Return on Assets: -12.49%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 5.15
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 629.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 10.50

Miscellaneous

• Outstanding Shares: 138,100,000
• Free Float: 132,162,000
• Market Cap: $2.23 billion
• Optionable: Optionable
• Beta: 0.93